Redeye comments on Optomed’s directed share issue, raising EUR4.1m. We are positive that the company has taken advantage of the strong share price development during the past month and believe there is no imminent capital need going forward. We adjust our fair value range accordingly to the announcement, resulting in a new base case of EUR8 (8.5).